American College of Toxicology 31st Annual Meeting

Preclinical testing for oncology drugs has become more streamlined with the finalization of the ICH guidance (S9) on oncology drug development. A successful new oncology drug typically enters patients with limited life expectancy, and the regulatory path of a small number of preclinical studies is sensible. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download